---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-003460"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:58:04.920183+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Rezolute shares patient testimonial with favorable results for ersodetug in Phase 2 study

## Summary
- Company released a pre-recorded video detailing a patient's experience in the Phase 2 trial of investigational drug ersodetug.
- Video notes favorable results for that single patient but cautions they may not be representative of broader trial outcomes.
- Ersodetug is not FDA-approved; no safety or efficacy determination has been made by the agency.
- Transcript filed as Exhibit 99.1 includes forward-looking statements and risk factors.
- No new quantitative clinical data or regulatory milestones disclosed in this filing.

## SEC filing metadata
- accession: 0001104659-25-003460
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465925003460/0001104659-25-003460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465925003460/tm253210d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-003460
- JSON: https://secwatch.observer/filing/0001104659-25-003460.json
- Plain text: https://secwatch.observer/filing/0001104659-25-003460.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.